ALB and autoimmune hepatitis: In this study, we first explored the potential activity of AuNCs in AIH treatment by using well-defined GSH-protected AuNCs (named GA) and then constructed an HSA-encapsulated AuNCs (named HA) with preferred liver targeting to improve the therapeutic efficacy for AIH.